Stage III Colon Cancer AJCC v8 Clinical Trials

17 clinical trials for Stage III Colon Cancer AJCC v8 across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Family Communications After Genetic Testing — RECRUITING · NA
• Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment — RECRUITING · PHASE2
• Designing a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers — RECRUITING · NA
• Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer — RECRUITING · PHASE2
• Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment — ACTIVE_NOT_RECRUITING
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair — ACTIVE_NOT_RECRUITING · PHASE3
• SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial — ACTIVE_NOT_RECRUITING · PHASE1
• LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study — COMPLETED · PHASE2
• Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer — COMPLETED · PHASE1
• Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial — TERMINATED
• Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer — WITHDRAWN · PHASE2
• Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer — OTHER · PHASE2
• Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer — TERMINATED · PHASE2

Refine this search